Skip to contentpdufa.bio

sotagliflozin SONATA-HCM (Phase 3)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

sotagliflozin SONATA-HCM (Phase 3) is a Lexicon Pharmaceuticals, Inc. program in symptomatic hypertrophic cardiomyopathy. Its next catalyst is a Readout in Q1 2027.

LXRX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Symptomatic hypertrophic cardiomyopathy. Sponsor: Lexicon Pharmaceuticals, Inc. (LXRX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027LXRX

Questions

When is sotagliflozin SONATA-HCM (Phase 3)'s next FDA decision or readout?

The next tracked catalyst for sotagliflozin SONATA-HCM (Phase 3) is a Readout in Q1 2027.

What happened at sotagliflozin SONATA-HCM (Phase 3)'s most recent FDA decision?

No FDA decision for sotagliflozin SONATA-HCM (Phase 3) is in our archive yet.

What is sotagliflozin SONATA-HCM (Phase 3) used for?

In our records sotagliflozin SONATA-HCM (Phase 3) is under review or in development for Symptomatic hypertrophic cardiomyopathy.

Who makes sotagliflozin SONATA-HCM (Phase 3)?

Lexicon Pharmaceuticals, Inc. (LXRX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.